DIRS.INFO The most relevant business & tech news

Pfizer CEO Albert Bourla speaks during the China Development Forum in Beijing on March 25, 2023. BEIJING — U.S. pharma giant Pfizer has signed an agreement with China to cooperate on improving the country's health coverage, according to the company. China in 2016 announced a "Healthy China 2030" plan for improving the country's public health services, medical industry and food and drug safety. The Covid-19 pandemic also highlighted shortfalls in China's still-developing public health system. Pfizer's memorandum of understanding with the Health China Research Center is set to support public health research and improve the health of rural populations, according to details released by Chinese state media.

Washington-based Seagen is a pioneer of antibody-drug conjugates, which work like "guided missiles" designed for a targeted destructive effect and spare healthy cells. The Pfizer logo is pictured on their headquarters building in the Manhattan borough of New York City, New York, U.S., November 9, 2020. The drugmaker expects more than $10 billion in sales from Seagen products in 2030, and another $15 billion from its other recent acquisitions. Pfizer said antitrust regulators could closely review the deal due to its size but eventually approve it. Pfizer rival Merck & Co Inc (MRK.N) and Seagen were in advanced deal talks last year but those reportedly collapsed over antitrust concerns.

☆ Pfizer’s $43 bln deal is a pricey pipeline fix
▼ + stars: | 2023-03-13 | by ( ) www.reuters.com time to read: +2 min

NEW YORK, March 13 (Reuters Breakingviews) - Pfizer (PFE.N) has found a partial, costly replacement for waning sales of Covid-19 vaccines. The $225 billion pharmaceutical giant said Monday it had agreed to shell out $43 billion for oncology specialist Seagen (SGEN.O), inclusive of net debt. Snag is, Pfizer’s return will probably be low, and the deal may not even receive antitrust approval. Add estimated savings of $1 billion and the result is $1.2 billion of operating profit after tax, assuming the statutory corporate rate. That’s about a 3% return on the purchase price, similar to what Breakingviews estimated when news of talks leaked in February.

☆ The Pfizer-Seagen deal has a hidden $1 billion warning for workers
▼ + stars: | 2023-03-13 | by ( Yeji Jesse Lee | ) www.businessinsider.com time to read: +2 min

While the deal bolsters Pfizer's cancer portfolio, it also mean cuts focused on "eliminating duplication"Pfizer said it is aiming for $1 billion in "cost efficiencies" within 3 years of the deal. Pharmaceutical giant Pfizer said on Monday that it would acquire drug developer Seagen in a massive $43 billion deal that would bolster its oncology portfolio. The acquisition is the largest biopharma deal since 2019 when AbbVie acquired Allergan for $63 billion, according to Stat News. Namely, Pfizer is aiming for $1 billion in "cost efficiencies" within three years of the deal closing, which could mean job cuts. Pfizer's deal for Seagen is expected to close in late 2023 or early 2024.

☆ Seagen has one of the greatest technologies to battle cancer: Pfizer CEO on acquisition
▼ + stars: | 2023-03-13 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailSeagen has one of the greatest technologies to battle cancer: Pfizer CEO on acquisitionAlbert Bourla, Pfizer CEO, joins 'Squawk on the Street' to discuss his thoughts on the company buying Seagen.

☆ Pfizer CEO says it will be able to deliver Seagen's cancer therapy at a scale not seen before with $43 billion deal
▼ + stars: | 2023-03-13 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +4 min

Pfizer CEO Albert Bourla on Monday said the pharmaceutical giant will be able to deliver Seagen's cancer therapy to the world "at a scale that has not been seen before" with its $43 billion acquisition. Seagen will bulk up Pfizer's cancer treatment portfolio, bringing four approved cancer therapies with combined sales of nearly $2 billion in 2022. "These medicines are on a strong growth trajectory, with significant lifecycle programs anticipated to drive continued impact uptake and growth," Bourla said on a conference call earlier Monday morning. Seagen expects to generate about $2.2 billion in revenue this year, representing 12% year-over-year growth, according to a Pfizer press release. Pfizer added that Seagen could contribute more than $10 billion in risk-adjusted sales by 2030, "with potential for significant growth" beyond that year.

☆ EU silence over Pfizer COVID contract talks is problem that won't go away -watchdog
▼ + stars: | 2023-03-01 | by ( Maggie Fick | ) www.reuters.com time to read: +3 min

[1/2] The European Ombudsman Emily O'Reilly speaks during an interview with Reuters in Brussels, Belgium February 28, 2023. The Commission said in June 2022 that it no longer had the texts, which later drew criticism from the EU ombudsman. O’Reilly argued many people would understand why von der Leyen approached Bourla to plead Europe’s case for vaccines, as tens of thousands of people on the continent were dying from COVID-19. It has proposed to other EU institutions that they do the same, the spokesperson added. In February, the New York Times said it was suing the Commission over failure to release the text messages.

☆ Eli Lilly recruits Black patients for Alzheimer trial as drugmakers seek more diversity in clinical studies
▼ + stars: | 2023-02-16 | by ( Bertha Coombs | ) www.cnbc.com time to read: +4 min

Eli Lilly drove two mobile labs to the Black women's gathering, to recruit older Black women for a new trial. The drug maker developed the labs on wheels in 2020, to keep its clinical trials going in the first year of the Covid pandemic. A study by the Alzheimer's Association found that 62% of African Americans think clinical research is biased against people of color. Decentralized trialsFinding and enrolling patients can be among the most costly and time-consuming part of clinical trials. By 2021, while advertising remained the top source, social media replaced doctors as the second most-likely way trial participants learned about clinical studies.

☆ From Apple to VW, CEOs Gradually Returning to China After Its Reopening
▼ + stars: | 2023-02-12 | by ( Dan Strumpf | Yoko Kubota | ) www.wsj.com time to read: 1 min

Volkswagen CEO Oliver Blume was among the first top executives from a multinational company to visit China since it scrapped most of its border restrictions. BEIJING—Top executives from multinational companies are trickling back into China with the country’s reopening, as Beijing seeks to restore confidence from global businesses in its struggling economy and attract investments. Volkswagen AG’s chief executive visited China from late January to early February, the company said, while Apple Inc. CEO Tim Cook and Pfizer Inc. CEO Albert Bourla are expected to visit next month, people familiar with the matter said. Ola Källenius , Mercedes-Benz Group AG’s chairman, also plans a visit to China, the company said.

☆ U.S. plans to stop buying Covid shots for the public this fall. Here's what that means
▼ + stars: | 2023-02-04 | by ( Spencer Kimball | ) www.cnbc.com time to read: +6 min

There is a federal program to provide free vaccines to children whose families or caretakers can't afford the shots. Sen. Bernie Sanders, I-Vt., slammed the vaccine price hike in a letter to Moderna's CEO last month. Under the ACA, private health insurance is required to cover all immunizations recommended by the CDC at no cost to the consumer. There may be a small number of legacy private health insurance plans from before the ACA that are not required to cover Covid vaccines, Cox said. Consumers could also see their health insurance premiums increase if Pfizer and Moderna hike the price of the shots, Cox said.

In 2023, it expects revenue to be $67 billion to $71 billion. Excluding the COVID-19 drugs, Pfizer expects 2023 revenue to grow 7% to 9%. Pfizer developed its COVID-19 vaccine with German partner BioNTech , and the companies split the profits. The U.S. drugmaker forecast 2023 sales of $13.5 billion from the shot, below Refinitiv estimates of $14.39 billion, and projected $8 billion in sales of Paxlovid, short of analysts' expectation of $10.33 billion. After that transition, the company hopes to roughly quadruple the U.S. price of the COVID-19 vaccine.

☆ The Covid pandemic drives Pfizer's 2022 revenue to a record $100 billion
▼ + stars: | 2023-01-31 | by ( Spencer Kimball | ) www.cnbc.com time to read: +2 min

The ongoing Covid-19 pandemic propelled pharmaceutical company Pfizer's earnings to a record $100 billion last year, almost $57 billion of which was driven by its vaccine and antiviral pill Paxlovid. The vaccine accounted for $37.8 billion, up just 3% from 2021, of Pfizer's total sales as demand for the shots slowed. But sales of its blockbuster antiviral treatment made up for that softening, surging to $18.9 billion in 2022, the first full-year that Paxlovid was on the market. Covid vaccines sales are projected to plummet by 64% this year to $13.5 billion from $37.8 billion in 2022. Paxlovid sales are expected to drop 58% to $8 billion in 2023 from $18.9 billion in 2022.

☆ The Covid sales boom is over for Pfizer
▼ + stars: | 2023-01-31 | by ( Paul R. La Monica | ) edition.cnn.com time to read: +3 min

New York CNN —Pfizer generated nearly $57 billion in combined sales last year from its Comirnaty Covid-19 vaccine and Paxlovid antiviral pill. Pfizer (PFE) told Wall Street Tuesday that it expects Covid-related sales to plunge to $21.5 billion this year… below Wall Street’s forecasts. Pfizer noted that it now expects to sell just $13.5 billion of its vaccine and $8 billion of the Paxlovid pill this year. Wall Street was expecting vaccine revenue of $14.4 billion and $10.3 billion of Paxlovid for 2023, according to estimates tracked by Refinitiv. Pfizer reported Comirnaty sales of $37.8 billion last year and revenue of $18.9 billion from Paxlovid.

Analysts say they have based their 2023 Paxlovid sales estimates primarily on public details of announced deals, with a token amount of estimated China sales from before the country dropped the Zero-COVID policy. Their current estimates for over $10 billion in 2023 Paxlovid sales is less than half the $22 billion Pfizer is expected to report for 2022, according to Refinitiv data. Billions of dollars in Paxlovid sales could be at stake for Pfizer. Even without a deal to sell Paxlovid broadly in China, the company can still sell it there on the private market. China is "probably the only region that we're modeling a year-over-year increase in 2023" for Paxlovid, Conover said.

☆ Moderna, Pfizer's new race: The RSV vaccine FDA approval process
▼ + stars: | 2023-01-18 | by ( Eric Rosenbaum | ) www.cnbc.com time to read: +8 min

Both companies have released results from RSV vaccine trials with efficacy results strong enough to expect expedited approval from the FDA. The companies — which have been involved in litigation brought by Moderna alleging mRNA patent infringement, a claim Pfizer disputes — are both expected the FDA approval process for the RSV vaccine to occur soon. We can use the same, the same equipment and raw materials as the Covid vaccine." The RSV approval process is just one part of a widening vaccine industry for these two companies. "Every strain is treated as suspicious and we start working on it to see if it can overcome the vaccine," Bourla said.

He heard at that time that Pfizer's (PFE.N) anti-viral drug Paxlovid was an effective treatment, but patients could only get it prescribed if they were admitted to hospital, and only if the drug was in stock. Li's experience, local media reports and online posts bear testimony to the difficulties faced obtaining Paxlovid in China through official channels. "Pfizer is actively collaborating with Chinese authorities and all stakeholders to secure an adequate supply of Paxlovid in China. We remain committed to fulfilling the COVID-19 treatment needs of Chinese patients and partnering with the Chinese government," the company said in a statement. PAXLOVID GIFTSeveral other people described to Reuters how they turned to the grey market to purchase Paxlovid.

☆ Chinese hospital says half of its staff got Covid
▼ + stars: | 2023-01-12 | by ( Evelyn Cheng | ) www.cnbc.com time to read: +3 min

Locals line up for medical treatment at the Beijing Hospital of Traditional Chinese Medicine on June 1, 2022. CFOTO | Future Publishing | Getty ImagesBEIJING — About half of the nearly 2,000 workers at the Beijing Hospital of Traditional Chinese Medicine got Covid-19 during the latest wave, director Liu Qingquan said Wednesday. Liu told reporters the workers all recovered by taking traditional Chinese medicine. China has encouraged the use of traditional Chinese medicine alongside Western treatment for Covid. Rather than pharmaceutical drugs, traditional Chinese medicine relies on herb-based remedies and natural methods to help the body heal itself.

☆ Pfizer CEO says there will be no generic Paxlovid for China
▼ + stars: | 2023-01-10 | by ( ) www.cnbc.com time to read: +1 min

An online pharmacy lists Pfizer's oral anti-Covid drug Paxlovid for 2,980 yuan per box in in Suqian, Jiangsu province, China on Dec. 13, 2022. Pfizer is not in talks with Chinese authorities to license a generic version of its Covid-19 treatment Paxlovid for use there, but is in discussions about a price for the branded product, Chief Executive Albert Bourla said on Monday. Reuters reported on Friday that China was in talks with Pfizer to secure a license that will allow domestic drugmakers to manufacture and distribute a generic version of the U.S. firm's Covid-19 antiviral drug Paxlovid in China. We have an agreement already for local manufacturing of Paxlovid in China. So we have a local partner that will make Paxlovid for us, and then we will sell it to the Chinese market."

☆ Pfizer not in talks on licensing generic COVID pill in China
▼ + stars: | 2023-01-10 | by ( ) www.reuters.com time to read: +1 min

[1/2] Paxlovid, Pfizer's anti-viral medication to treat the coronavirus disease (COVID-19), is displayed in this picture illustration taken October 7, 2022. A morning and an evening does consists of one white 100-milligram tablet of Ritonavir and two pink 150-milligram tablets of PF-07321332. REUTERS/Wolfgang Rattay/IllustrationNEW YORK, Jan 9 (Reuters) - Pfizer Inc (PFE.N) Chief Executive Albert Bourla said on Monday that the company is not in talks with Chinese authorities to license a generic version of its COVID-19 treatment Paxlovid for use there. Bourla, speaking at J.P. Morgan's healthcare conference in San Francisco, also said that talks with China on future pricing for the treatment had broken off after China had asked for a lower price than Pfizer is charging for most lower middle income countries. "They are the second highest economy in the world and I don't think that they should pay less than El Salvador," Bourla said.

☆ Pfizer working to send COVID pill Paxlovid to China - CNBC
▼ + stars: | 2023-01-09 | by ( ) www.reuters.com time to read: +1 min

Jan 9 (Reuters) - Pfizer Inc (PFE.N) is working with Chinese authorities to send its COVID-19 pill, Paxlovid, to the country that is dealing with a surge in COVID-19 cases, Chief Executive Officer Albert Bourla said in an interview with CNBC on Monday. In February last year, China approved Paxlovid to treat high-risk patients in several provinces. Pfizer has also reached an agreement to export Paxlovid to China through a local company to make the medicine more widely available. China has also been in talks with the drugmaker to secure a license that will allow domestic drugmakers to manufacture and distribute a generic version of Paxlovid in China, Reuters reported last week, citing sources. Chinese hospitals have been under intense pressure after the government abruptly abandoned its "zero-COVID" policy last month, sending infections soaring.

☆ Pfizer CEO: 2022 was one of the most successful years in our corporate history
▼ + stars: | 2023-01-09 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailPfizer CEO: 2022 was one of the most successful years in our corporate historyCNBC's Meg Tirrell sits down with Pfizer CEO Albert Bourla to discuss the Covid crisis and Pfizer's future in producing 19 new products in the next 18 months.

☆ CIOs Nominate Their Favorite Reads of 2022
▼ + stars: | 2022-12-28 | by ( Tom Loftus | ) www.wsj.com time to read: +9 min

Chief information officers, ever alert to any development in a field that only hurtles forward, largely reflected that alacrity in their choice of reading during 2022. PREVIEWChris Bedi, chief digital information officer, ServiceNow Inc. Photo: IBM Corp.Ron Guerrier, chief information officer, HP Inc. Photo: Cisco Systems Inc.Fletcher Previn, chief information officer, Cisco Systems Inc. Photo: Home Depot Inc.Fahim Siddiqui, chief information officer, Home Depot Inc.

☆ Mike Sievert of T-Mobile is the CNN Business CEO of the Year
▼ + stars: | 2022-12-26 | by ( Paul R. La Monica | ) edition.cnn.com time to read: +8 min

T-Mobile’s solid performance on Wall Street was one big reason why CEO Mike Sievert is the CNN Business pick for CEO of the Year. CNN Business spoke to Sievert about how T-Mobile has continued to perform well in a super competitive business. T-Mobile CEO Mike Sievert talks to employees at a 2022 company event. That has led to higher expenses, but Sievert said T-Mobile is less worried about inflation than other consumer firms. Prepared for more competitionSievert, who has been with T-Mobile since 2012, took over as CEO in 2020 from long-time CEO John Legere.

☆ Fact Check-Pfizer CEO is not resigning and did not say mRNA vaccines 'don’t work'
▼ + stars: | 2022-12-13 | by ( Reuters Fact Check | ) www.reuters.com time to read: +2 min

Social media users in early December 2022 have falsely claimed that Albert Bourla, the CEO of Pfizer, has resigned after allegedly saying that mRNA vaccines are unsafe and ineffective. A Pfizer spokesperson told Reuters via email, “Albert Bourla continues to serve as the chairman and CEO of Pfizer. Multiple studies have shown that mRNA vaccines are safe and effective (here), (here), (here), (here). Pfizer confirmed that CEO Albert Bourla is not resigning. Update Dec. 16, 2022: Updates headline to clarify that Albert Bourla is not resigning and did not say mRNA COVID-19 vaccines don’t work.

☆ FDA expected to decide on Pfizer RSV vaccine for older adults by May 2023
▼ + stars: | 2022-12-07 | by ( Spencer Kimball | ) www.cnbc.com time to read: +2 min

The Food and Drug Administration is expected to decide by spring whether to approve Pfizer's vaccine to prevent respiratory syncytial virus, or RSV, in adults ages 60 and older. Pfizer, in a statement Wednesday, said the FDA has accepted its RSV vaccine candidate for review under an expedited process that reduces the approval process by four months. RSV is a common respiratory virus that causes cold like symptoms in most people, but it can result in severe illness in infants and older adults. Between 60,000 and 120,000 older adults are hospitalized with RSV every year and 6,000 to 10,000 older adults die from the virus. Pfizer's vaccine candidate was about 86% effective in preventing severe lower respiratory tract illness, defined as three or more symptoms.

Search resuls for: "Bourla"

25 mentions found